ArticleBiomedical journal2026
Inhibition of the 4-hydroxynonenal-regulated JNK/c-Jun pathway improves bleomycin-induced lung fibrosis.
Article in Biomedical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Glycyrrhizin alleviatesJournal of thoracic disease · 2026Article
- Metabolic cell death: ferroptosis, cuproptosis, and disulfidptosis as a unified framework for targeting metabolic vulnerabilities in disease.Apoptosis : an international journal on programmed cell death · 2026Review
- Tanshinone IIA Attenuates Pulmonary Fibrosis via Dual Inhibition of JNK and Smad Signaling.Antioxidants (Basel, Switzerland) · 2026Article
- Displaced minds: ecologies of depression.Biomedical journal · 2026Article
- From Alveolar Injury to Precision Perioperative Care: Integrating Molecular Biomarkers and Technology-Enabled Strategies for Prolonged Air Leak After Lung Resection.Mediators of inflammation · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLipid peroxidation and 4-hydroxynonenal (4-HNE) contribute to oxidative stress-related tissue damage, but their roles in pulmonary fibrosis remain unclear. We examined their involvement in bleomycin-induced pulmonary fibrosis. MATERIALS AND
methodsLung fibrosis model mice were used to assess collagen deposition, lipid peroxidation markers, and oxidative stress. Ferroptosis inhibitors ferrostatin-1 (Fer-1) and deferoxamine (DFO) were administered to the mice. In vitro, murine lung epithelial (MLE-12) cells were treated with bleomycin, with or without lipid peroxidation inhibitors, and analyzed for oxidative stress and apoptosis. 4-HNE expression in idiopathic pulmonary fibrosis lung tissues was assessed using immunohistochemistry.
resultsBleomycin increased deposition of collagen and levels of 4-HNE and malondialdehyde levels while decreasing the glutathione/glutathione disulfide ratio. Fer-1 and DFO improved pulmonary function, reduced fibrosis, and restored the glutathione/glutathione disulfide ratio. In vitro, lipid peroxidation inhibition suppressed bleomycin-induced cell death and oxidative stress. Direct 4-HNE treatment induced apoptosis and lipid peroxidation, implicating 4-HNE in epithelial injury. 4-HNE upregulation was linked to increased transforming growth factor-β expression via c-Jun amino-terminal kinase/c-Jun signaling. Fer-1 and DFO mitigated these effects. Human idiopathic pulmonary fibrosis tissues exhibited elevated 4-HNE, correlating with fibrosis severity.
conclusionsLipid peroxidation and 4-HNE play key roles in pulmonary fibrosis progression. Their regulation of transforming growth factor-β expression suggests targeting lipid peroxidation as a potential therapeutic strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.